

# Study examines neurological outcomes for TBI treatments

July 1 2014

---

In patients with a traumatic brain injury (TBI), neither the administration of the hormone erythropoietin (EPO) or maintaining a higher hemoglobin concentration through blood transfusion resulted in improved neurological outcome at 6 months, according to a study in the July 2 issue of *JAMA*. Transfusing at higher hemoglobin concentrations was associated with a higher risk of adverse events.

Patients with severe [traumatic brain injury](#) commonly develop anemia. For patients with neurological injury, anemia is a potential cause of secondary injury, which may worsen neurological outcomes. Treatment of anemia may include transfusions of packed red blood cells or administration of [erythropoietin](#). There is limited information about the effect of erythropoietin or a high hemoglobin transfusion threshold (if the hemoglobin concentration drops below a certain level, a transfusion is performed) after a TBI, according to background information in the article.

Claudia S. Robertson, M.D., of the Baylor College of Medicine, Houston, and colleagues conducted a [randomized clinical trial](#) that included 200 patients (erythropoietin, n = 102; placebo, n = 98) with a closed head injury at neurosurgical intensive care units in two U.S. level I trauma centers between May 2006 and August 2012. Patients were enrolled within 6 hours of injury and had to be unable to follow commands after initial stabilization. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (n = 74). There were 99 patients assigned to a hemoglobin transfusion

threshold of 7 g/dL and 101 patients assigned to 10 g/dL.

In the placebo group, 34 patients (38.2 percent) recovered to a favorable outcome (defined as good recovery and moderate disability, as measured by a functional assessment inventory) compared with 17 patients (48.6 percent) in the erythropoietin 1 group (first dosing regimen) and 17 patients (29.8 percent) in the erythropoietin 2 group (second dosing regimen). Thirty-seven patients (42.5 percent) assigned to the transfusion threshold of 7 g/dL recovered to a favorable outcome compared with 31 patients (33.0 percent) assigned to the transfusion threshold of 10 g/dL.

There was a higher incidence of thromboembolic events for the [transfusion](#) threshold of 10 g/dL (21.8 percent) vs (8.1 percent) for the threshold of 7 g/dL.

"Among patients with closed head injury, neither the administration of erythropoietin nor maintaining [hemoglobin concentration](#) of at least 10 g/dL resulted in improved neurological outcome at 6 months. These findings do not support either approach in [patients](#) with traumatic brain injury," the authors conclude.

**More information:** [DOI: 10.1001/jama.2014.6490](https://doi.org/10.1001/jama.2014.6490)

Provided by The JAMA Network Journals

Citation: Study examines neurological outcomes for TBI treatments (2014, July 1) retrieved 7 May 2024 from <https://medicalxpress.com/news/2014-07-neurological-outcomes-tbi-treatments.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.